{"entity":{"type":"insider","cik":"0001835498","url":"/insider/0001835498","json_url":"/insider/0001835498.json","name":"Huntsman Ronald Kirk","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":13,"n_filings":10,"first":"2020-12-14","last":"2023-06-20","span_basis":"filed_date"},"name_variants":[{"name":"Huntsman Ronald Kirk","source":"filing","n_filings":10,"first_seen":"2020-12-14","last_seen":"2023-06-20"}],"transactions":[{"id":7976296,"accession":"0001493152-23-021910","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-23-021910","line_url":"/filing/0001493152-23-021910#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14000.0,"shares_display":"14,000","price_per_share":0.53,"price_display":"0.53","price_state":"stated","total_value":7420.0,"total_display":"7,420.00","total_whole":"7,420","shares_owned_after":86521.0,"shares_owned_after_display":"86,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-20","filed_date":"2023-06-20","scope":"insider"},{"id":8712572,"accession":"0001493152-23-021751","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001493152-23-021751","line_url":"/filing/0001493152-23-021751","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":0.5366666666666666,"price_display":"0.54","price_state":"stated","total_value":8050.0,"total_display":"8,050.00","total_whole":"8,050","shares_owned_after":67521.0,"shares_owned_after_display":"67,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-16","filed_date":"2023-06-20","scope":"insider","n_lines":2},{"id":8712564,"accession":"0001493152-23-021751","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-23-021751","line_url":"/filing/0001493152-23-021751#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21.0,"shares_display":"21","price_per_share":0.5,"price_display":"0.50","price_state":"stated","total_value":10.5,"total_display":"10.50","total_whole":"11","shares_owned_after":57521.0,"shares_owned_after_display":"57,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-15","filed_date":"2023-06-20","scope":"insider"},{"id":8020676,"accession":"0001493152-23-021525","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-23-021525","line_url":"/filing/0001493152-23-021525#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":0.49,"price_display":"0.49","price_state":"stated","total_value":4900.0,"total_display":"4,900.00","total_whole":"4,900","shares_owned_after":57500.0,"shares_owned_after_display":"57,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-14","filed_date":"2023-06-15","scope":"insider"},{"id":6898660,"accession":"0001493152-22-036727","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-036727","line_url":"/filing/0001493152-22-036727#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":0.5,"price_display":"0.50","price_state":"stated","total_value":10000.0,"total_display":"10,000.00","total_whole":"10,000","shares_owned_after":47500.0,"shares_owned_after_display":"47,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-23","filed_date":"2022-12-28","scope":"insider"},{"id":6970270,"accession":"0001493152-22-015773","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-22-015773","line_url":"/filing/0001493152-22-015773#line-2","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":1.83,"price_display":"1.83","price_state":"stated","total_value":7320.0,"total_display":"7,320.00","total_whole":"7,320","shares_owned_after":27500.0,"shares_owned_after_display":"27,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-01","filed_date":"2022-06-03","scope":"insider"},{"id":6970261,"accession":"0001493152-22-015773","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-015773","line_url":"/filing/0001493152-22-015773#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8000.0,"shares_display":"8,000","price_per_share":2.03,"price_display":"2.03","price_state":"stated","total_value":16240.0,"total_display":"16,240.00","total_whole":"16,240","shares_owned_after":23500.0,"shares_owned_after_display":"23,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-31","filed_date":"2022-06-03","scope":"insider"},{"id":4184347,"accession":"0001493152-21-023354","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-023354","line_url":"/filing/0001493152-21-023354#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":4.31,"price_display":"4.31","price_state":"stated","total_value":21550.0,"total_display":"21,550.00","total_whole":"21,550","shares_owned_after":15500.0,"shares_owned_after_display":"15,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-21","filed_date":"2021-09-22","scope":"insider"},{"id":5152687,"accession":"0001493152-21-020536","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-020536","line_url":"/filing/0001493152-21-020536#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":15000.0,"total_display":"15,000.00","total_whole":"15,000","shares_owned_after":10500.0,"shares_owned_after_display":"10,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-17","filed_date":"2021-08-18","scope":"insider"},{"id":4990454,"accession":"0001493152-21-012901","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-012901","line_url":"/filing/0001493152-21-012901#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":5.38,"price_display":"5.38","price_state":"stated","total_value":21520.0,"total_display":"21,520.00","total_whole":"21,520","shares_owned_after":5500.0,"shares_owned_after_display":"5,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-25","filed_date":"2021-05-25","scope":"insider"},{"id":3066064,"accession":"0001493152-20-024277","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-20-024277","line_url":"/filing/0001493152-20-024277#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":7.2669,"price_display":"7.27","price_state":"stated","total_value":7266.9,"total_display":"7,266.90","total_whole":"7,267","shares_owned_after":1500.0,"shares_owned_after_display":"1,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-23","filed_date":"2020-12-23","scope":"insider"},{"id":2072068,"accession":"0001493152-20-023466","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-20-023466","line_url":"/filing/0001493152-20-023466#line-1","is_derivative":false,"issuer_cik":"0001716166","issuer_name":"Vivos Therapeutics, Inc.","issuer_ticker":"VVOS","issuer_name_source":null,"issuer_url":"/issuer/0001716166","owner_cik":"0001835498","owner_name":"Huntsman Ronald Kirk","owner_display_name":"Huntsman Ronald Kirk","owner_url":"/insider/0001835498","role":"Director, Officer (Chief Executive Officer), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":8.5,"price_display":"8.50","price_state":"stated","total_value":4250.0,"total_display":"4,250.00","total_whole":"4,250","shares_owned_after":500.0,"shares_owned_after_display":"500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-11","filed_date":"2020-12-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":13,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":13,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":13},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001716166","name":"Vivos Therapeutics, Inc.","url":"/issuer/0001716166","role":"Director, Officer (Chief Executive Officer), Ten percent owner","n_filings":10,"first_seen":"2020-12-14","last_seen":"2023-06-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001835498","retrieved_at":"2026-08-25T06:05:05+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}